desipramine has been researched along with Hyperphagia in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Hyperphagia: Ingestion of a greater than optimal quantity of food.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, PL | 1 |
| Wells, LA | 1 |
| Cunningham, CJ | 1 |
| Ilstrup, DM | 1 |
1 trial available for desipramine and Hyperphagia
| Article | Year |
|---|---|
Treating bulimia with desipramine. A double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anorexia Nervosa; Clinical Trials as Topic; Depressive Disorder; Desipramine; Fee | 1986 |